4. Clark WG and Lipton JM. Changes in body temperature after admin- 23.
istration of adrenergic and serotonergic agents and related drugs including
antidepressants: II. Neurosci Biobehav Rev 10: 153–220, 1986. 24.
5. Clinckers R, Smolders I, Meurs A, Ebinger G, and Michotte Y.
Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by DA and 5-HT receptors. J Neurochem 89: 834 –
843, 2004. 25.
6. Cooper BR, Wang CM, Cox RF, Norton R, Shea V, and Ferris RM.
Evidence that the acute behavioral and electrophysiological effects of
bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. 26.
Neuropharmacology 11: 133–141, 1994.
7. Cox B and Lee TF. Further evidence for a physiological role for
hypothalamic dopamine in thermoregulation in the rat. J Physiol 300:
7–17, 1980. 27.
8. Gordon CJ. Thermal biology of the laboratory rat. Physiol Behav 47:
963–991, 1990.
9. Hasegawa H, Yazawa T, Yasumatsu M, Otokawa M, and Aihara Y.
Alteration in dopamine metabolism in the thermoregulatory center of 28.
exercising rats. Neurosci Lett 289: 161–164, 2000.
10. Hasegawa H, Ishiwata T, Saito T, Yazawa T, Aihara Y, and Meeusen
R. Inhibition of the preoptic area and anterior hypothalamus by tetrodo-29.
toxin alters thermoregulatory functions in exercising rats. J Appl Physiol
98: 1458 –1462, 2005.
11. Hillegaart V. Effects of local application of 5-HT and 8-OH-DPAT into
30.
the dorsal and median raphe nuclei on core temperature in the rat.
Psychopharmacology (Berl) 103: 291–296, 1991.
12. Hyttel J. Citalopram—pharmacological profile of a specific serotonin
uptake inhibitor with antidepressant activity. Prog Neuropsychopharma-31.
col Biol Psychiatry 6: 277–295, 1982.
13. Ishiwata T, Saito T, Hasegawa H, Yazawa T, Otokawa M, and Aihara
Y. Changes of body temperature and extracellular serotonin level in the
32.
preoptic area and anterior hypothalamus after thermal or serotonergic
pharmacological stimulation of freely moving rats. Life Sci 75: 2665–
33.
2675, 2004.
14. Jacobs BL and Azmitia EC. Structure and function of the brain serotonin
system. Physiol Rev 72: 165–229, 1992.
15. Liu YL, Connoley IP, Harrison J, Heal DJ, and Stock MJ. Comparison
34.
of the thermogenic and hypophagic effects of sibutramine's metabolite 2
and other monoamine reuptake inhibitors. Eur J Pharmacol 452: 49 –56,
2002.
35.
16. Liu YL, Connoley IP, Harrison J, Heal DJ, and Stock MJ. Pharmacological characterization of the thermogenic effect of bupropion. Eur
J Pharmacol 498: 219 –225, 2004.
17. Meeusen R, Roeykens J, Magnus L, Keizer H, and De Meirleir K.
Endurance performance in humans: the effect of a dopamine precursor or
a specific serotonin (5-HT2A/2C) antagonist. Int J Sports Med 18: 571– 36.
577, 1997.
18. Meeusen R, Piacentini MF, Van Den Eynde S, Magnus L, and De
Meirleir K. Exercise performance is not influenced by a 5-HT reuptake 37.
inhibitor. Int J Sports Med 22: 329 –336, 2001.
19. Myers RD and Yaksh TL. Feeding and temperature responses in the
unrestrained rat after injections of cholinergic and aminergic substances
into the cerebral ventricles. Physiol Behav 3: 917–928, 1968. 38.
20. Nestler EJ, Hyman SE, and Malenka RC. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience. New York: McGraw-Hill,
2001.
21. Nomikos GG, Damsma G, Wenkstern D, and Fibiger HC. Acute 39.
effects of bupropion on extracellular dopamine concentrations in rat
striatum and nucleus accumbens studied by in vivo microdialysis. Neuro- 40.
psychopharmacology 2: 273–279, 1989.
Pannier JL, Bouckaert JJ, and Lefebvre RA. The antiserotonin agent
pizotifen does not increase endurance performance in humans. Eur J Appl
Physiol 72, 175–178, 1995.
